Table 1 Baseline characteristics of a cohort of 91 HIV-infected infants followed up at Baylor-Uganda
From: Virologic, immunologic and clinical response of infants to antiretroviral therapy in Kampala, Uganda
Variable | Median (IQR) | N (%) |
|---|---|---|
Age (months) | 6.2 (4.04-9.0) | |
0-6 | 43 (47.3) | |
7-12 | 48 (52.7) | |
Sex | ||
Male | 38 (41.8) | |
Female | 53 (58.2) | |
CD4 Percent | 20 (15-29) | |
Viral load (copies/ml) | ||
<100,000 | 14 (18.2) | |
100,000-750,000 | 29 (37.7) | |
>750,000 | 34 (44.1) | |
WHO clinical stage | ||
1 | 13 (14.4) | |
2 | 27 (30.0) | |
3 | 32 (35.6) | |
4 | 18 (20.0) | |
ART regimen | ||
ZDV+3TC+NVP | 14 (16.7) | |
ZDV+3TC+Lop/r | 13 (15.5) | |
D4T+3TC+NVP | 30 (35.7) | |
D4T+3TC+Lop/r | 16 (19.0) | |
Other | 11 (13.1) | |
Weight/Age z-score | ||
Median (IQR) | −2.2 (-3.89 - -1) | |
<-3SD score | 33 (36.3) | |
≥-3SD to <-2SD | 24 (26.4) | |
≥-2≤SD to < -1SD | 11 (12.1) | |
≥-1SD | 23 (25.2) | |
Height/Age z-score | ||
Median | −1.92 (-3.05 - -1.02) | |
<-3SD score | 23 (25.3) | |
≥-3SD to<-2SD | 20 (21.9) | |
≥-2SD to<-1SD | 26 (28.6) | |
≥-1SD | 22 (24.2) |